Key Highlights from Revive Therapeutics' Annual Shareholder Meeting
Recently, Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a company dedicated to researching and developing therapeutics aimed at infectious diseases and rare disorders, held an important gathering to discuss the future of the organization. During this annual and special meeting, shareholders engaged actively in the voting process that took place on a significant date.
Board of Directors Election
At the forefront of the meeting was the election of new board members who will participate in steering the future of Revive. The shareholders were pleased to elect:
Newly Elected Directors
1. Michael Frank, Chief Executive Officer
2. Joshua Herman, Independent Director
3. Andrew Lindzon, Independent Director
4. William Jackson, Independent Director
5. Christian Scovenna, Independent Director
Shareholder Approvals
Shareholders also provided their approval for several key initiatives:
Appointment of the Company’s Auditor
The shareholders approved Horizon Assurance LLP as the Company’s auditor for the upcoming fiscal year, ensuring professional and oversight standards are maintained.
Auditor Remuneration
In addition, the directors were authorized to determine how the auditor’s remuneration will be fixed, an important step in managing financial aspects effectively.
Incentive Stock Option Plan
Another resolution that received favorable votes was the continuation of the Company’s 10% rolling incentive stock option plan for the year ahead, indicating commitment to motivating and compensating talent effectively.
Listening to Shareholders
In a move towards transparency and accountability, the Board of Directors also considered shareholder feedback and chose not to proceed with the proposal intending to consolidate the Company’s outstanding Common Shares. This decision reflects a strong engagement with shareholders and a willingness to be adaptive to their concerns.
Understanding Revive Therapeutics
Revive Therapeutics is at the forefront of life sciences innovation, dedicating efforts to develop therapeutics that target a variety of ailments, especially infectious diseases and medical countermeasures. The Company is actively pursuing regulatory avenues that provide expedited pathways for drug development, such as Emergency Use Authorizations and Breakthrough Therapy designations issued by the FDA. One exciting project currently under investigation is the use of Bucillamine for treating long COVID and nerve agent exposure, showing promise in addressing recent health crises.
Advancements in Psilocybin-Based Therapies
In addition to the above initiatives, Revive Therapeutics is making strides in developing Psilocybin-based therapeutics. These innovative approaches aim to open new doors in treatment availability for various health conditions, signaling positive developments in the holistic healthcare sphere.
Contact Information for Revive Therapeutics
For further details, interested parties may reach out to:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Phone: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Frequently Asked Questions
What was the main focus of the recent shareholder meeting?
The meeting primarily focused on electing new board members and approving key corporate initiatives.
Who were the newly elected members of the board?
The newly elected board includes Michael Frank, Joshua Herman, Andrew Lindzon, William Jackson, and Christian Scovenna.
What auditor was appointed for Revive Therapeutics?
Horizon Assurance LLP was appointed as the Company’s auditor for the upcoming fiscal year.
What options were approved for the shareholders?
Shareholders approved the continuation of the 10% rolling incentive stock option plan and the remuneration for the auditor.
What areas is Revive Therapeutics focusing on with its developments?
Revive is concentrating on therapeutics for infectious diseases, long COVID, and explores advancements in Psilocybin therapies.
